LifeMD Reports Fourth Quarter and Full Year 2025 Results

Core Insights - LifeMD, Inc. reported strong financial results for Q4 and the full year 2025, indicating a robust growth trajectory in its virtual healthcare services [2][3][5]. Financial Performance - Full year 2025 revenue increased by 25% to $194.1 million, while adjusted EBITDA rose by 309% to $15.3 million [7]. - Q4 revenue grew by 4% to $46.9 million, with adjusted EBITDA increasing by 348% to $4.8 million [7][8]. - The company exited 2025 with approximately $36.8 million in cash and no debt, enhancing its financial stability for future investments [5][7]. Business Growth and Strategy - LifeMD's weight management business is experiencing record patient sign-ups, with over 80% of new patients initiating branded therapy [3][7]. - The company launched oral Wegovy to address barriers in cost and access for patients, positioning itself to capitalize on a significant market opportunity [3]. - LifeMD's infrastructure is expected to cover approximately 220 million Americans by the end of Q2 2026, supported by a specialized provider group and national pharmacy operations [4][7]. Subscriber Metrics - The number of active telehealth subscribers increased by 16% to approximately 323,000 by the end of Q4 2025 [8]. - The company anticipates annualized run-rate revenue to exceed $250 million and adjusted EBITDA to exceed $25 million by Q4 2026, driven by growth in GLP-1 and women's health segments [5][15]. Market Positioning - LifeMD is uniquely positioned for long-term leadership in the virtual healthcare market, with ongoing collaborations with major healthcare and pharmaceutical brands [4][3]. - The company emphasizes its differentiated specialty offerings in men's and women's health, which are expected to scale significantly [4].